Quantcast
Last updated on April 18, 2014 at 11:11 EDT

Latest Andrew Witty Stories

2009-02-05 07:25:00

LONDON, February 5 /PRNewswire-FirstCall/ -- In a video interview Andrew Witty, GlaxoSmithKline CEO, described the pharmaceutical group's results as "robust" in a year that was "always going to be challenging". GSK also announced that it will cease providing EPS guidance, to allow a focus on longer term strategic goals. Describing 2008 as a strategic turning point for GSK Mr Witty said: "We started to make very clear what it would take to really make this company strong over the...

2009-01-29 15:31:00

PHILADELPHIA, Jan. 29 /PRNewswire-FirstCall/ -- On Thursday, February 5th, GlaxoSmithKline plc (NYSE: GSK) will announce its year end financial results for the year ended December 31, 2008. The announcement is scheduled for release to the London Stock Exchange at approximately 7:00 AM Eastern Standard Time (EST). At 9:00 AM EST Andrew Witty, Chief Executive Officer, and Julian Heslop, Chief Financial Officer will hold a briefing meeting for analysts and investors. The meeting is available...

2008-07-21 12:01:26

Biota Holdings Limited (ASX: BTA) today announced it had concluded its litigation against GlaxoSmithKline (GSK). The announcement followed formal mediation between by the parties ordered by the Victorian Supreme Court. The mediation provided the parties with the opportunity to resolve their differences and eliminate the uncertainty and costs associated with the legal process. Biota and GSK have agreed to normalise their relationship to pursue the best interests of Relenza, with senior...

2006-02-01 09:25:00

By Ben Hirschler, European Pharmaceuticals Correspondent LONDON -- GlaxoSmithKline Plc continued its roll-out of new products on Wednesday, winning fresh regulatory approvals for two niche treatments to fight diabetes and cancer. Europe's biggest drug maker said it was launching Avandaryl, a two-in-one diabetes pill, in the United States and had been given a green light in Europe to market Hycamtin -- already used to fight ovarian tumors -- as a treatment for lung cancer. Both approvals had...